Dr. Arab is an Associate Professor of Medicine at the Division of Gastroenterology, Hepatology, and Nutrition of Virginia Commonwealth University School of Medicine. He serves as the Inaugural Director of Alcohol Sciences at the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Dr. Arab trained as Gastroenterologist and Transplant Hepatologist specialist at the Catholic University of Chile and at the Mayo Clinic, Rochester, MN. Dr.
Mazen Noureddin, MD, MHSc, did his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow.
Aleksander Krag, MD, PhD, MBA is Professor and Department Chair, Department of Gastroenterology and Hepatology Odense University Hospital, Director of Centre for Liver Research (FLASH) Odense University Hospital and DIAS Chair of Health Sciences, University of Southern Denmark. He also served as Vice-Secretary and then as Secretary General of European Association for the Study of Liver (EASL) 2021-2025.
H. Marvin Pollard Collegiate Professor of Gastroenterology III
Professor of Internal Medicine and Surgery
Director, Morphomics Analysis Group
University of Michigan Medical School
Chief, Gastroenterology and Hepatology Section
Associate Chief of Specialty Care and Access, Medicine Service
VA Ann Arbor Healthcare System
Teresa (Terry) Wright is currently Vice President and Clinical Research Head for Hepatology at GSK with responsibility for oversight of clinical development of investigational agents for patients with viral, metabolic and autoimmune liver diseases.
Marc Ghany, MD, MHSc, FAASLD is a Senior Investigator and Chief of the Clinical Hepatology Research Section, Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH).
Dr. Fabien Zoulim, MD, PhD is a Professor of Medicine at Lyon I University and Medical Director of the Hepatology Department at the Hospices Civils de Lyon.
His research interests focus on the understanding of viral persistence to discover and develop novel treatments to cure chronic HBV and HDV infections.
Dr. Perrillo is an internationally recognized expert in the management of hepatitis B virus. He has over 40 years experience with clinical research of chronic hepatitis B during which time he has made several important contributions in the field of HBV epidemiology, vaccinology, serologic testing, and advances in antiviral therapy. His current research interest focuses on new approaches to post transplant management of patients transplanted for chronic hepatitis B.
Dr. Lok graduated from the University of Hong Kong Medical School. She completed her hepatology training in London under Dame Sheila Sherlock. She was on the faculty at the University of Hong Kong until she moved to the United States in 1992.
Dr. Lok's research focuses on natural history and treatment of hepatitis B and C. Her research also includes liver cancer and fatty liver. She has published more than 600 papers including each edition of the American Association for the Study of Liver Diseases (AASLD) guideline on hepatitis B.
Harvey J Alter, has been designated a Distinguished NIH Investigator, only one of 23 NIH scientists to hold that distinction. In his long career in clinical research, Dr. Alter has played a key role in the discovery of two hepatitis viruses, namely hepatitis B virus (HBV) and the non-A, non-B virus, later designated the hepatitis C virus (HCV). In long-term prospective studies, Alter helped define the natural history of NANB/HCV infection and proved its frequent progression to chronic hepatitis and its evolution to cirrhosis and liver related mortality.